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Abstract
Ž .Mitral regurgitation MR is a frequent complication of end-stage heart failure. Historically, these patients were either
managed medically or with mitral valve replacement, both associated with poor outcomes. Mitral valve repair via an
‘undersized’ annuloplasty repair is safe and effectively corrects MR in heart-failure patients. All of the observed changes
contribute to reverse remodeling and restoration of the normal left-ventricular geometric relationship. Mitral valve repair
offers a new strategy for patients with MR and end-stage heart failure. Q European Society of Cardiology. All rights reserved.
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1. Introduction
Heart failure is currently one of the leading causes
of hospitalization. Heart failure will become even
more of a medical challenge as average life ex-
pectancy continues to rise. Despite significant im-
provements in maximal medical management, approx-
imately 50% of patients with heart failure are dead
within 3 years of clinical presentation. While heart
transplantation is now considered standard treatment
for selected patients with severe heart failure, it is
only applicable to a small % of these patients. Trans-
plantation is limited, both by the small number of
donor hearts available, and its inapplicability in the
older patient or those with comorbid medical condi-
tions that would preclude them from consideration
w xfor transplantation. 1 In an effort to address this
problem, alternative and new surgical strategies have
evolved, including coronary artery revascularization
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w x w x2,3 , mechanical circulatory support 4]6 , cardio-
w x w xmyoplasty 2,7 , left ventricular myoreduction 8,9 ,
w xand mitral valve repair 10]14 .
Functional mitral regurgitation is a significant com-
plication of end-stage heart failure, and may affect
almost all heart-failure patients as a pre-terminal or
terminal event. The mitral regurgitation develops sec-
ondary to an alteration in the annular-ventricular
w x w xapparatus 15 and altered ventricular geometry 16 ,
which results in incomplete leaflet coaptation. In is-
chemic heart failure this can be attributed to papillary
or lateral wall muscle dysfunction, and in non-ischemic
heart failure it can be ascribed to annular dilation
w xand chordal tethering 17 , all as a result of dysfunc-
tional remodeling. Mitral regurgitation exacerbates
w xthe volume overload 18 of the already dilated ventri-
cle, with further progression of annular dilation, in-
creased left ventricular wall tension, worsening mitral
regurgitation and increased failure, which predicts a
w xpoor outcome 19 .
Historically, the surgical approach to patients with
functional mitral regurgitation was mitral valve re-
placement, and little was understood of the adverse
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consequences that interruption of the annulus-
papillary muscle continuity had on left ventricular
w xsystolic function 20 . This procedure was associated
w xwith very high mortality rates 21,22 . It is in this
population of patients that the concept of the ‘pop-off’
effect of mitral regurgitation originated, that is, rever-
sal of blood flow was somehow beneficial to the
patient in heart failure. It has been demonstrated in a
number of studies that preservation of the annulus-
papillary muscle continuity is of paramount impor-
tance to preservation of left ventricular function
w x23,24 . It was the excision and disruption of the
subvalvular apparatus that accounted for the signifi-
cant loss of systolic function and led to the poor
outcome in the earlier patients who underwent mitral
w xvalve replacement 25,26 . Preservation of the mitral
valve apparatus and left ventricle in mitral valve re-
Žpair in rheumatic and degenerative mitral valve dis-
.ease has been demonstrated to enhance and main-
tain left ventricular function and geometry with an
w xassociated decrease in wall stress 27,28 . This proce-
dure has been shown to be safe, with a significant
decrease in operative morbidity and mortality, and
w xgood long-term outcomes 29]32 .
In order to address the issue of heart failure and
mitral regurgitation, the anatomy of the mitral valve
must first be understood. The determination of mitral
competence depends on an understanding that the
mitral valve apparatus consists of the annulus, leaflets,
chordae tendinae, papillary muscles, and the entire
left ventricle. Maintenance of the chordal, annular
and subvalvular continuity and mitral geometric rela-
tionships are important in the preservation of overall
ventricular function, and may be even more important
in those patients with compromised left-ventricular
function. When selecting a surgical approach to the
problem of heart failure, it must, therefore, first be
recognized that this is a ventricular problem, and
therefore a solution directed solely at the mitral valve,
neglecting the left ventricle, is not ideal. Excision of a
portion of the left ventricular wall does not address
the issue directly, and in fact can further disrupt the
mitral valve apparatus by disruption of the left ven-
tricular wall.
2. Surgical procedure
At the University of Michigan between June 1993
and January 1999, 92 patients with end-stage heart
failure and refractory severe mitral regurgitation were
studied prospectively. All patients had NYHA class
III or IV heart failure despite receiving maximal
Žmedical therapy digoxin, diuretics, and afterload-re-
.ducing agents , and had severe left ventricular systolic
dysfunction as defined by an ejection fraction -25%
on angiography or radionuclide studies. Patient ages
Ž .ranged from 33 to 81 years mean 60"5 years .
Patients were equally divided between non-ischemic
dilated heart failure and end-stage ischemic heart
failure without ongoing ischemia, as defined by a
negative dobutamine echocardiogram andror a nega-
tive positron emission tomography scan, and there-
fore would not be expected to gain any improvement
from a coronary artery revascularization procedure.
The mean duration of documented heart failure was
Ž .3"6 years range 0]16 . Pre-operative ejection frac-
Ž .tion ranged from 8 to 24% mean 14% . At surgery,
all patients underwent mitral valve reconstruction with
implantation of an undersized flexible annuloplasty,
remodeling ring; no patients underwent a complex
mitral valve repair. Additional procedures included,
38 DeVega tricuspid annuloplasties, seven single
coronary artery bypass grafts in patients with coro-
nary artery disease discovered as an incidental find-
ing, and implantation of one ICD patch. Mitral valve
reconstruction was performed via median sternotomy
with cardiopulmonary bypass, utilizing hypothermic,
blood cardioplegic arrest in patients undergoing a first
operation, and via right thoracotomy, utilizing cold
fibrillatory arrest in 38 redo patients who had under-
gone prior coronary artery bypass grafting.
3. Results
Intra-operative transesophageal echocardiography
revealed no mitral regurgitation in most patients, and
mild regurgitation in seven at the end of the proce-
dure. All patients were weaned from cardiopulmonary
bypass and maintained in the immediate post-oper-
ative period on milrinone and norepinephrine infu-
sions.
There was one intra-operative mortality from right
ventricular failure, in a patient who died despite both
Ž .the use of the intra-aortic balloon pump IABP and
mechanical right ventricular assist device support. Five
patients required IABP support, but none required
the use of a left ventricular assist device.
In the postoperative period in our study, seven
patients required longer than 24 h of mechanical
ventilator support, and only three patients for longer
than 48 h. There was one late wound infection. There
were no other in-hospital deaths and the mean length
Ž .of stay following the procedure was 9"4 range 4]37
Ždays. There were five 30-day mortalities overall oper-
.ative mortality was 5% , one due to cardiac failure,
one due to a stroke, two due to multisystem organ
failure, primarily related to underlying pulmonary
failure, and the one intra-operative death mentioned
previously.
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ŽWe followed these patients for 1]68 months mean
.38 , with a 1- and 2-year actuarial survival of 80 and
70%, respectively. All patients remained on medical
therapy for their heart failure. Patients did not un-
dergo routine placement of ICD devices, nor were
they placed on amiodarone therapy unless clinically
indicated. On immediate post-operative echocardio-
grams, the mean trans-mitral diastolic gradient was
Ž .3"1 mm Hg range 2]6 , there were no cases of
Ž .mitral stenosis or systolic anterior motion SAM . At
24-month follow-up all remaining patients, without
loss to follow-up, were in NYHA Class I or II, with a
mean ejection fraction of 26%, and with a demon-
strated improvement in ejection fraction in every
patient. A marked reduction in regurgitant volume
and fraction was demonstrated. The NYHA class im-
proved for every patient individually, and from a
mean of 3.2"0.2 to 1.8"0.4 for the entire group. All
patients reported subjective improvement in functio-
nal status. In those patients for whom preoperative
data was available for comparison, peak maximal
volume of O use during a 6-min walk rose signifi-2
cantly, from a mean of 14.5 to 18.6 ml O rkgrmin.2
The matched preoperative and 24-month postopera-
tive echocardiographic data are recorded in Table 1.
All patients had a reduction in sphericity index and
regurgitant fraction. All patients demonstrated im-
provement in left ventricular ejection fraction, cardiac
output, and end diastolic volumes. There have been
26 late deaths in this group of patients. This number
includes three patients who had further progression
of disease and had undergone transplantation, and
two related to complications following other operative
procedures. The other deaths have resulted from pro-
Ž .gression of heart failure ns8 , despite no significant
return of mitral regurgitation, sudden ventricular ar-
Ž .rhythmia ns12, 8 in ischemic patients and one
suicide.
4. Discussion
For patients with dilated heart failure, mortality is
directly related to the severity of left ventricular sys-
w xtolic dysfunction 19 . In addition, increased chamber
sphericity and, more importantly, the presence of
w xmitral insufficiency 33 are markers of a worse prog-
nosis. In review of these types of patients, 1-year
mortality has been reported between 54 and 70%.
Furthermore, in a study of 28 patients awaiting trans-
plantation, with an ejection fraction of 25% or less,
1-year survival was only 46%, and independent pre-
dictors of death were low forward-stroke volumes, a
history of ventricular arrhythmia, and mitral regurgi-
w xtation 34 . The patients presented in our study there-
fore represent a group with a very high-predicted
mortality.
The pathogenesis of mitral regurgitation-related
myopathy is multifactorial. In the absence of organic
disease, mitral regurgitation is predominantly thought
to occur as a result of progressive dilation of the
mitral annulus, with subsequent loss of coaptation of
the valve leaflets. A large leaflet area is normally
required for coaptation, because mitral leaflet area is
2.5 times greater than the area of the mitral valve
orifice. As more mitral leaflet tissue is utilized for
coverage of the enlarging mitral valve orifice, a criti-
cal reduction in the leaflet tissue available for coapta-
tion is reached, and a central regurgitant jet of
w x‘functional’ insufficiency begins to develop 15,35 .
Therefore, the most significant determinant of mitral
valve coaptation, leaflet orifice area, and mitral regur-
gitation is the dimensions of the mitral valve annulus.
The left ventricular dimension appears to be a less
important factor in functional mitral regurgitation;
chordal length and papillary muscle length are not
significantly different in people with idiopathic heart
w xfailure with or without mitral regurgitation 15 .
In ischemic heart failure, the mechanisms that con-
tribute to mitral regurgitation are complex. They may
include ‘functional’ mitral regurgitation, through dila-
tion of the mitral valve annulus, and ‘papillary muscle
dysfunction’, which is an unsuccessful coordination of
the entire mitral valve apparatus rather than simply
w xan isolated disorder of the papillary muscle 36 . These
ischemia-related changes are also thought to result in
an insufficient area of coaptation of the mitral leaflets.
In a recent study of patients with severe heart
failure who were managed with pharmacological
Žagents diuretics, nitrates and afterload-reducing
Table 1
Echocardiographic data in heart-failure patients
aECHO parameter Pre-operative Post-operative P value
Ž .End diastolic volume ml 281"86 206"88 -0.001
Ž .Ejection fraction % 16"5 26"8 0.008
Ž .Regurgitant fraction % 70"12 13"10 -0.001
Ž .Cardiac output lrmin 3.1"1.0 5.2"0.8 0.001
Ž .Sphericity index DrL 0.82"0.10 0.74"0.07 0.005
a 24 months.
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Table 2
Cytokine and receptor levels in heart-failure patients
TNF-a TNF-R1 TNF-R2 IL-6 IL6-R
Ž . Ž . Ž . Ž . Ž .pgrml pgrml pgrml pgrml ngrml
Pre-op. 3.5"1.3 931"187 1989"381 6.1"6.6 36.0"5.2
Ž .Post-op. 6 month 2.8"1.1 774"177 1450"254 2.9"1.8 31.2"8.1
P value 0.02 -0.01 -0.01 0.13 0.15
.agents , the observed decrease in filling pressure and
systemic vascular resistance led to a reduction in the
dynamic mitral regurgitation associated with their
heart failure. This was attributed to a reduction in the
regurgitant orifice area related to the decrease in left
w xventricular volume and annular distension 37 . This
complex relationship between mitral annular area and
leaflet coaptation may explain why, paradoxically, an
undersized ‘valvular’ repair can help a ‘muscular’
problem. Although significant undersizing of the mi-
tral annulus was employed in our study to over-cor-
rect for the zone of coaptation, no mitral stenosis was
induced, nor was any SAM of the anterior leaflet
noted. SAM was avoided, due to widening of the
aorto-mitral angle and increased left ventricular size
seen in myopathic patients. In addition, acute remod-
eling of the base of the heart from the undersizing of
the mitral annular ring may also contribute to the
improvement seen in these myopathic hearts. This
may re-establish the ellipsoid shape and somewhat
normal geometry to the base of the left ventricle.
Increases in left ventricular preload, wall tension,
diastolic volume, and stroke volume, are all docu-
mented ventricular adaptations to severe mitral re-
gurgitation. Maintenance of forward flow becomes
difficult, because up to 50% of the stroke volume is
ejected into the left atrium, even before the aortic
w xvalve opens 38 . Eliminating the regurgitant volume
can increase ventricular efficiency dramatically.
Successful mitral valve repair may have beneficial
effects on coronary flow. One study assessed coronary
flow in patients without coronary artery disease be-
w xfore and after mitral valve reconstruction 39 . Coro-
nary flow reserve was limited in patients with mitral
regurgitation due to an increase in basal coronary
flow and flow velocity, which was related to hypertro-
Ž .phy and increased preload left ventricular wall stress .
The restriction in coronary flow reserve improved
following mitral valve reconstruction because of a
reduction in the basal coronary flow and flow velocity
once the left ventricular preload, work and mass were
w xreduced 39 . Based on this study, a restriction in the
coronary flow reserve would seem probable in patients
with mitral regurgitation and heart failure, and an
improvement in flow reserve and velocity would be
expected following mitral valve repair.
Heart failure is a clinical syndrome resulting from
diverse and complex mechanisms. Proinflammatory
Ž .cytokines, including tumor necrosis factor-a TNF-a ,
IL-1, IL-2 and IL-6, may not only be produced by the
stressed myocardium, but also be responsible, in part,
w xfor myocardial depression 40]43 . Studies have de-
monstrated that this proinflammatory cytokine may
play a role in the development of left ventricular
dysfunction, heart failure, hypotension, and pulmo-
w xnary edema 44]47 . There are two forms of TNF-a-
specific receptors: TNF-R1 and -R2. Both receptors
are found in equal proportions in the normal myo-
cardium and TNF-a binds with equal affinity to both
receptors. The negative inotropic effects of TNF-a
are mediated primarily by its interaction with TNF-R1.
The expression of myocardial TNF-Rs is down-regu-
lated in the presence of heart failure, similar to that
w xseen with the b-adrenergic receptors 44,48 . The cir-
culating, or soluble, forms of TNF-Rs are elevated in
patients with heart failure, suggesting that these re-
w xceptors may be ‘shed’ from the myocardial cells 49 .
The circulating TNF-Rs can neutralize the biological
w xeffects of circulating TNF-a 50 . Based on these
observations, it has been postulated that the cardiac-
tissue response to increased TNF-a levels is to in-
crease the level of soluble TNF receptors in order to
decrease the amount of bioactive TNF-a that can
w xpotentially stimulate cardiac cells 44 . At the Univer-
sity of Michigan we have measured levels of TNF-a,
soluble TNF-R1 and -R2, IL-6 and IL-6 receptors in
the pre- and post-operative period in patients under-
going mitral valve repair in the presence of heart
Ž .failure Table 2 . The levels of these cytokines and
their respective receptors were all decreased in these
patients 6 months after mitral reconstruction. Further
studies are being conducted, in which the soluble
recombinant form of TNF-R is being administered to
heart-failure patients in the hope of decreasing some
w xof the clinical manifestations of failure 44 .
As the availability of transplantation for treatment
for patients with end-stage heart failure is limited,
there has been recent interest in the altered geometry
of the left ventricle in patients with severe dysfunc-
tion. This innovative work was initially described by
Batista, who states that all mammalian hearts share
the same ratio of massrdiameter, regardless of the
size of the heart. The formula that is common to all
hearts should be a muscle mass that is four times the
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Ž 3.radius cubed Ms4=R . Batista proposed that
those hearts that do not comply with this relationship
should undergo an operative procedure to restore the
w xratio back to normal 8,9 . Surgeons have attempted
to normalize this relationship by left ventricular my-
oreduction surgery, also called partial left ventricular
reduction surgery, reduction myoplasty or the Batista
procedure. Batista initially reported an operative
mortality of 5%, a 30-day mortality of 22%, and a
2-year survival of 55%. Unfortunately, complete and
long-term follow-up was not available for these
w xpatients 9,51]53 . This procedure has met with vary-
ing degrees of success in the United States and world-
w xwide 53]57 . The Cleveland Clinic series of 62
Ž .patients 95% idiopathic dilated cardiomyopathy re-
ported a 3.5% hospital mortality with seven late deaths
w xand a 1-year actuarial survival of 82% 54 . All of the
cases routinely had a mitral valve repair or replace-
ment as part of the myoreduction procedure, which
may have contributed to the relative success of the
procedure in this center.
Mitral valve reconstruction alone also re-estab-
lishes a more normal left ventricular massrvolume
w xratio without the loss of myocardial mass 11,13 . The
average left ventricular volume at 24-month follow-up
in our study was over 200 ml, still quite large, while
with the left ventricular myoreduction procedure,
Batista has demonstrated acute reduction of LV
volumes to approximately 90]100 ml at the time of
operation. There is no loss of ventricular mass with
the mitral valve reconstruction alone; however, an
appropriate massrvolume ratio is restored. Impor-
tantly, there is an acceptable surgical mortality, both
at 30 days and 1 year, for mitral valve reconstruction,
which is equivalent to, or lower than, that reported
w xfor left ventricular myoreduction procedures 51]57 .
One must differentiate the effect of abolishing mi-
tral regurgitation alone versus the addition of the
myoreduction. In dog models, left ventricular remod-
eling may be rapid and complete, with resultant re-
gurgitant fractions of less than 30% after correction
w xof the mitral regurgitation alone 58 . In the Univer-
sity of Michigan study, a decrease in sphericity index
and left ventricular volume measurements were de-
monstrated post-operatively, and it is in these patients
that the negative cycle of heart failure is interrupted
and the surgical unloading of the left ventricle is
achieved. These patients may be undergoing slow
reverse remodeling due to the alteration of the angu-
lation of the base of the heart, stabilization of the
mitral annulus, or left ventricular unloading. Benefi-
cial remodeling tends to occur more frequently in the
patients with idiopathic, as opposed to those with
ischemic, heart failure. In the hearts with end-stage
ischemic heart failure the potential for remodeling
may be limited, due to presence of scar in the ventric-
ular wall.
5. Conclusion
In conclusion, mitral reconstruction via an annulo-
plasty ring effectively corrects mitral regurgitation in
heart-failure patients and is a relatively safe proce-
dure in a high-risk population. Not only does it ap-
pear to improve survival, but also functional status,
often remarkably. While longer-term follow-up is nec-
essary with a greater number of patients, we are
encouraged by these results, and feel that mitral
reconstruction offers a new strategy for end-stage
heart failure.
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